199 related articles for article (PubMed ID: 26277372)
1. TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood.
Coutinho DF; Monte-Mór BC; Vianna DT; Rouxinol ST; Batalha AB; Bueno AP; Boulhosa AM; Fernandez TS; Pombo-de-Oliveira MS; Gutiyama LM; Abdelhay E; Zalcberg IR
Leuk Res; 2015 Oct; 39(10):1103-8. PubMed ID: 26277372
[TBL] [Abstract][Full Text] [Related]
2. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.
Liu X; Zhang G; Yi Y; Xiao L; Pei M; Liu S; Luo Y; Zhong H; Xu Y; Zheng W; Shen J
Leuk Lymphoma; 2013 Nov; 54(11):2466-73. PubMed ID: 23432690
[TBL] [Abstract][Full Text] [Related]
3. Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms.
Seethy AA; Pethusamy K; Kushwaha T; Kumar G; Talukdar J; Chaubey R; Sundaram UD; Mahapatra M; Saxena R; Dhar R; Inampudi KK; Karmakar S
BMC Cancer; 2023 Oct; 23(1):1035. PubMed ID: 37884893
[TBL] [Abstract][Full Text] [Related]
4. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
[TBL] [Abstract][Full Text] [Related]
5. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes.
Gurnari C; Pagliuca S; Guan Y; Adema V; Hershberger CE; Ni Y; Awada H; Kongkiatkamon S; Zawit M; Coutinho DF; Zalcberg IR; Ahn JS; Kim HJ; Kim DDH; Minden MD; Jansen JH; Meggendorfer M; Haferlach C; Jha BK; Haferlach T; Maciejewski JP; Visconte V
Blood Adv; 2022 Jan; 6(1):100-107. PubMed ID: 34768283
[TBL] [Abstract][Full Text] [Related]
6. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.
Scopim-Ribeiro R; Machado-Neto JA; Campos Pde M; Silva CA; Favaro P; Lorand-Metze I; Costa FF; Saad ST; Traina F
Eur J Haematol; 2015 May; 94(5):413-8. PubMed ID: 25200248
[TBL] [Abstract][Full Text] [Related]
7. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
[TBL] [Abstract][Full Text] [Related]
8. TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
Yun J; Ji YS; Jang GH; Lim SH; Kim SH; Kim CK; Bae SB; Won JH; Park SK
Curr Issues Mol Biol; 2021 Aug; 43(2):917-931. PubMed ID: 34449560
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
10. TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression.
Takayama K; Misawa A; Suzuki T; Takagi K; Hayashizaki Y; Fujimura T; Homma Y; Takahashi S; Urano T; Inoue S
Nat Commun; 2015 Sep; 6():8219. PubMed ID: 26404510
[TBL] [Abstract][Full Text] [Related]
11. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.
Pronier E; Almire C; Mokrani H; Vasanthakumar A; Simon A; da Costa Reis Monte Mor B; Massé A; Le Couédic JP; Pendino F; Carbonne B; Larghero J; Ravanat JL; Casadevall N; Bernard OA; Droin N; Solary E; Godley LA; Vainchenker W; Plo I; Delhommeau F
Blood; 2011 Sep; 118(9):2551-5. PubMed ID: 21734233
[TBL] [Abstract][Full Text] [Related]
14. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.
Mohamedali AM; Smith AE; Gaken J; Lea NC; Mian SA; Westwood NB; Strupp C; Gattermann N; Germing U; Mufti GJ
J Clin Oncol; 2009 Aug; 27(24):4002-6. PubMed ID: 19528370
[TBL] [Abstract][Full Text] [Related]
15. [An update on epigenetic regulator gene mutations and pathogenesis of myelodysplastic syndromes].
Wang JY; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1303-9. PubMed ID: 22040993
[TBL] [Abstract][Full Text] [Related]
16. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
[TBL] [Abstract][Full Text] [Related]
17. Tet2 restrains inflammatory gene expression in macrophages.
Cull AH; Snetsinger B; Buckstein R; Wells RA; Rauh MJ
Exp Hematol; 2017 Nov; 55():56-70.e13. PubMed ID: 28826859
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.
Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD
Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175
[TBL] [Abstract][Full Text] [Related]
19. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation.
Song SJ; Ito K; Ala U; Kats L; Webster K; Sun SM; Jongen-Lavrencic M; Manova-Todorova K; Teruya-Feldstein J; Avigan DE; Delwel R; Pandolfi PP
Cell Stem Cell; 2013 Jul; 13(1):87-101. PubMed ID: 23827711
[TBL] [Abstract][Full Text] [Related]
20. TET2 gene expression and 5-hydroxymethylcytosine level in multiple sclerosis peripheral blood cells.
Calabrese R; Valentini E; Ciccarone F; Guastafierro T; Bacalini MG; Ricigliano VA; Zampieri M; Annibali V; Mechelli R; Franceschi C; Salvetti M; Caiafa P
Biochim Biophys Acta; 2014 Jul; 1842(7):1130-6. PubMed ID: 24735979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
